Skip to main content
Erschienen in: Tumor Biology 8/2016

02.03.2016 | Original Article

Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression

verfasst von: Fengkun Du, Yan Li, Wensheng Zhang, Shubha P. Kale, Harris McFerrin, Ian Davenport, Guangdi Wang, Elena Skripnikova, Xiao-Lin Li, Nathan J. Bowen, Leticia B McDaniels, Yuan-Xiang Meng, Paula Polk, Yong-Yu Liu, Qian-Jin Zhang

Erschienen in: Tumor Biology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Patients with advanced epithelial ovarian cancer often experience disease recurrence after standard therapies, a critical factor in determining their five-year survival rate. Recent reports indicated that long-term or short-term survival is associated with varied gene expression of cancer cells. Thus, identification of novel prognostic biomarkers should be considered. Since the mouse genome is similar to the human genome, we explored potential prognostic biomarkers using two groups of mouse ovarian cancer cell lines (group 1: IG-10, IG-10pw, and IG-10pw/agar; group 2: IG-10 clones 2, 3, and 11) which display highly and moderately aggressive phenotypes in vivo. Mice injected with these cell lines have different survival time and rates, capacities of tumor, and ascites formations, reflecting different prognostic potentials. Using an Affymetrix Mouse Genome 430 2.0 Array, a total of 181 genes were differentially expressed (P < 0.01) by at least twofold between two groups of the cell lines. Of the 181 genes, 109 and 72 genes were overexpressed in highly and moderately aggressive cell lines, respectively. Analysis of the 109 and 72 genes using Ingenuity Pathway Analysis (IPA) tool revealed two cancer-related gene networks. One was associated with the highly aggressive cell lines and affiliated with MYC gene, and another was associated with the moderately aggressive cell lines and affiliated with the androgen receptor (AR). Finally, the gene enrichment analysis indicated that the overexpressed 89 genes (out of 109 genes) in highly aggressive cell lines had a function annotation in the David database. The cancer-relevant significant gene ontology (GO) terms included Cell cycle, DNA metabolic process, and Programmed cell death. None of the genes from a set of the 72 genes overexpressed in the moderately aggressive cell lines had a function annotation in the David database. Our results suggested that the overexpressed MYC and 109 gene set represented highly aggressive ovarian cancer potential biomarkers while overexpressed AR and 72 gene set represented moderately aggressive ovarian cancer potential biomarkers. Based on our knowledge, the current study is first time to report the potential biomarkers relevant to different aggressive ovarian cancer. These potential biomarkers provide important information for investigating human ovarian cancer prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342:257–63.CrossRefPubMed Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342:257–63.CrossRefPubMed
3.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed
4.
Zurück zum Zitat du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.CrossRefPubMed du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.CrossRefPubMed
5.
Zurück zum Zitat Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.CrossRefPubMed Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.CrossRefPubMed
6.
Zurück zum Zitat Skirnisdottir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:236–44.CrossRefPubMed Skirnisdottir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:236–44.CrossRefPubMed
7.
Zurück zum Zitat Nikas JB, Boylan KL, Skubitz AP, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informat. 2011;10:233–47.CrossRef Nikas JB, Boylan KL, Skubitz AP, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informat. 2011;10:233–47.CrossRef
8.
Zurück zum Zitat Kamieniak MM, Rico D, Milne RL, Munoz-Repeto I, Ibanez K, Grillo MA, et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol. 2015;9:422–36.CrossRefPubMed Kamieniak MM, Rico D, Milne RL, Munoz-Repeto I, Ibanez K, Grillo MA, et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol. 2015;9:422–36.CrossRefPubMed
9.
Zurück zum Zitat Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91.CrossRefPubMed Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91.CrossRefPubMed
10.
Zurück zum Zitat Li XL, Zhang DQ, Wang D, Knight DS, Yin L, Bao J, et al. In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity. Tumour Biol. 2008;29:359–70.CrossRefPubMed Li XL, Zhang DQ, Wang D, Knight DS, Yin L, Bao J, et al. In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity. Tumour Biol. 2008;29:359–70.CrossRefPubMed
11.
Zurück zum Zitat Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol. 2005;26:236–44.CrossRefPubMed Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol. 2005;26:236–44.CrossRefPubMed
12.
Zurück zum Zitat D’Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J. 2008;2:7–12.CrossRefPubMed D’Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J. 2008;2:7–12.CrossRefPubMed
13.
Zurück zum Zitat D’Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res. 2004;10:8132–41.CrossRefPubMed D’Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res. 2004;10:8132–41.CrossRefPubMed
14.
Zurück zum Zitat Saldanha SN, Tollefsbol TO. Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol. 2014;229:393–406.CrossRefPubMed Saldanha SN, Tollefsbol TO. Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol. 2014;229:393–406.CrossRefPubMed
15.
Zurück zum Zitat Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19:992–7.CrossRefPubMed Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19:992–7.CrossRefPubMed
16.
17.
Zurück zum Zitat Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18:538–48.CrossRefPubMed Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18:538–48.CrossRefPubMed
18.
Zurück zum Zitat Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep. 2013;30:3–10.PubMed Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep. 2013;30:3–10.PubMed
19.
Zurück zum Zitat Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 2007;17:505–16.PubMed Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 2007;17:505–16.PubMed
20.
Zurück zum Zitat Baserga R, Porcu P, Sell C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv. 1993;16:201–13.PubMed Baserga R, Porcu P, Sell C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv. 1993;16:201–13.PubMed
21.
Zurück zum Zitat Zimonjic DB, Popescu NC. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol. 2012;41:393–406.PubMedPubMedCentral Zimonjic DB, Popescu NC. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol. 2012;41:393–406.PubMedPubMedCentral
22.
Zurück zum Zitat Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87–94.CrossRefPubMed Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87–94.CrossRefPubMed
23.
Zurück zum Zitat Tamai Y, Taketo M, Nozaki M, Seldin MF. Mouse Elk oncogene maps to chromosome X and a novel Elk oncogene (Elk3) maps to chromosome 10. Genomics. 1995;26:414–6.CrossRefPubMed Tamai Y, Taketo M, Nozaki M, Seldin MF. Mouse Elk oncogene maps to chromosome X and a novel Elk oncogene (Elk3) maps to chromosome 10. Genomics. 1995;26:414–6.CrossRefPubMed
24.
Zurück zum Zitat Pickeral OK, Li JZ, Barrow I, Boguski MS, Makalowski W, Zhang J. Classical oncogenes and tumor suppressor genes: a comparative genomics perspective. Neoplasia. 2000;2:280–6.CrossRefPubMedPubMedCentral Pickeral OK, Li JZ, Barrow I, Boguski MS, Makalowski W, Zhang J. Classical oncogenes and tumor suppressor genes: a comparative genomics perspective. Neoplasia. 2000;2:280–6.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69:111–7.CrossRefPubMed Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69:111–7.CrossRefPubMed
26.
Zurück zum Zitat Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene. 2004;330:101–14.CrossRefPubMed Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene. 2004;330:101–14.CrossRefPubMed
27.
Zurück zum Zitat Enrietto PJ. The myc oncogene in avian and mammalian carcinogenesis. Cancer Surv. 1987;6:85–99.PubMed Enrietto PJ. The myc oncogene in avian and mammalian carcinogenesis. Cancer Surv. 1987;6:85–99.PubMed
28.
Zurück zum Zitat Slotman BJ, Nauta JJ, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 1990;66:740–4.CrossRefPubMed Slotman BJ, Nauta JJ, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 1990;66:740–4.CrossRefPubMed
29.
Zurück zum Zitat Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617–26.CrossRefPubMed Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617–26.CrossRefPubMed
30.
Zurück zum Zitat Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A. 2004;101:2434–9.CrossRefPubMedPubMedCentral Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A. 2004;101:2434–9.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep. 2007;18:1347–56.PubMed Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep. 2007;18:1347–56.PubMed
32.
Zurück zum Zitat Morgenbesser SD, DePinho RA. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin Cancer Biol. 1994;5:21–36.PubMed Morgenbesser SD, DePinho RA. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin Cancer Biol. 1994;5:21–36.PubMed
33.
Zurück zum Zitat Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol. 1987;28:137–50.CrossRefPubMed Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol. 1987;28:137–50.CrossRefPubMed
34.
Zurück zum Zitat Somay C, Grunt TW, Mannhalter C, Dittrich C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer. 1992;66:93–8.CrossRefPubMedPubMedCentral Somay C, Grunt TW, Mannhalter C, Dittrich C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer. 1992;66:93–8.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 1995;15:1501–10.PubMed Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 1995;15:1501–10.PubMed
36.
Zurück zum Zitat Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987;26:393–7.CrossRefPubMed Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987;26:393–7.CrossRefPubMed
37.
Zurück zum Zitat Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 1998;17:231–7.PubMed Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 1998;17:231–7.PubMed
38.
Zurück zum Zitat Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997;66:250–4.CrossRefPubMed Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997;66:250–4.CrossRefPubMed
39.
Zurück zum Zitat Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96:5722–7.CrossRefPubMedPubMedCentral Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96:5722–7.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.CrossRefPubMedPubMedCentral Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis. PLoS One. 2013;8:e56381.CrossRefPubMedPubMedCentral Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis. PLoS One. 2013;8:e56381.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R, Leone G. Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 2003;278:42041–9.CrossRefPubMed de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R, Leone G. Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 2003;278:42041–9.CrossRefPubMed
43.
Zurück zum Zitat Liebermann DA, Hoffman B. Prostate cancer: JunD, Gadd45a and Gadd45g as therapeutic targets. Cell Cycle. 2011;10:3428.CrossRefPubMed Liebermann DA, Hoffman B. Prostate cancer: JunD, Gadd45a and Gadd45g as therapeutic targets. Cell Cycle. 2011;10:3428.CrossRefPubMed
44.
Zurück zum Zitat Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Schoeb TR, et al. G2E3 is a dual function ubiquitin ligase required for early embryonic development. J Biol Chem. 2008;283:22304–15.CrossRefPubMedPubMedCentral Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Schoeb TR, et al. G2E3 is a dual function ubiquitin ligase required for early embryonic development. J Biol Chem. 2008;283:22304–15.CrossRefPubMedPubMedCentral
Metadaten
Titel
Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression
verfasst von
Fengkun Du
Yan Li
Wensheng Zhang
Shubha P. Kale
Harris McFerrin
Ian Davenport
Guangdi Wang
Elena Skripnikova
Xiao-Lin Li
Nathan J. Bowen
Leticia B McDaniels
Yuan-Xiang Meng
Paula Polk
Yong-Yu Liu
Qian-Jin Zhang
Publikationsdatum
02.03.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4518-4

Weitere Artikel der Ausgabe 8/2016

Tumor Biology 8/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.